CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins83% CONFIDENCEOverall confidence: 83%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
AbbVie's 8-K press release is datelined 'NORTH CHICAGO, Ill., SAN FRANCISCO and BOSTON, June 22, 2026' and says the investor call was 'today, June 22'; BioPharm International[4] (23 June 2026) reports the same deal.On 22 June 2026 AbbVie agreed to acquire Apogee Therapeutics for US$135.11 per share in cash, a total equity value of about US$10.9 billion, adding the IL-13 antibody zumilokibart for atopic dermatitis.
$10.9B
1.00
